Copenhagen Infrastructure Partners interconnector portfolio in the North Sea takes a leap forward 28-02-2023, 18:30

‘Reconnections’, TIM at Rimini Meeting with exhibition on floods 24-08-2023, 17:08

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00